Advertisement

Topics

Novartis eyes Regeneron's blockbuster Eylea franchise

06:00 EDT 20 Jun 2017 | BioPharmaDive

Brolucizumab, pegged for a blockbuster future by Novartis, matched up to Regeneron's eye drug across two Phase 3 studies. 

Original Article: Novartis eyes Regeneron's blockbuster Eylea franchise

NEXT ARTICLE

More From BioPortfolio on "Novartis eyes Regeneron's blockbuster Eylea franchise"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...